Snapshot
3M Co reported $6.52B of revenue in Q3 2025, up 3.5% year over year, with diluted EPS of $1.55 and an operating margin of 22.2%.
- Revenue
- $6.52B
- YoY growth
- +3.5%
- Diluted EPS
- $1.55
- Operating margin
- 22.2%
What management said
- •Please note that today's earnings release and slide presentation accompanying this call are posted on the homepage of our investor relations website at 3M.com.
- •The 3M team delivered another strong quarter in Q3 with organic sales growth of 3.2%.
- •The fourth consecutive quarter of positive organic growth across all three business groups against a macro backdrop that is largely unchanged and generally soft.
- •Our 3M Excellence operating model helped drive operating margins up 170 basis points, earnings per share up 10% to $2.19, and free cash flow of $1.3 billion, a conversion of 111%.
- •Our strong performance through the first three quarters of the year enables us to increase our earnings per share guidance to $7.95 to $8.05.
- •On the back of a strong Q3, we now expect full-year organic sales growth to be greater than 2%, with adjusted free cash flow conversion remaining above 100%.
- •Our cross-selling program continues to outperform our expectations, and we have nearly doubled the pipeline since last quarter and closed on nearly $30 million of new business.
- •Another launch in the consumer business expanded our size offering in our Filtrete business, giving us broader coverage of the market and leading to high single-digit growth in the category in Q3.
- •Last quarter, we launched a new lightweight wireframe self-contained breathing apparatus, which contributed to our high teens growth this quarter in our SCBA business and SIBG.
- •Our efforts here are driving margin expansion, improving customer service, increasing asset utilization, and reducing cost of poor quality.
- •Year to date, OEE is about 63%, up 300 basis points versus last year.
- •Our cost of poor quality in the quarter was 5.7%, down 40 basis points sequentially and 150 basis points year over year.
What went well
- •Q3 organic sales growth of 3.2%, the fourth consecutive quarter of positive organic growth across all three business groups, with operating margins up 170 bps to 24.7%, EPS up 10% to $2.19 and free cash flow of $1.3 billion (111% conversion).
- •Raised full-year EPS guidance to $7.95-$8.05 (from $7.75-$8.00) and now expects full-year organic sales growth greater than 2%.
- •Innovation momentum: 70 new products launched in the quarter (196 year-to-date, up ~70%), now expecting over 250 launches in 2025; five-year new product sales up 30% in Q3.
- •Operational excellence records: OTIF reached 91.6% (up 200 bps sequentially, 300 bps year-over-year, best in 20+ years); OEE ~63% year-to-date (up 300 bps); cost of poor quality 5.7% (down 40 bps sequentially, 150 bps year-over-year).
- •Commercial excellence delivered cross-selling pipeline nearly doubled with ~$30 million of new business closed; SIBG grew 4.1% (highest since 2018 ex-COVID), with China up high single digits and the U.S. up nearly 4%.
What went wrong
- •Roofing granules softened over the prior 90 days from the slow housing market and weak consumer sentiment.
- •Commercial vehicles weakened, down north of 20% in the back half of the year from emissions trends, tariffs and other factors.
- •TEBG margins were down about 20 bps in the quarter, the most impacted by PFAS stranded costs and mix.
- •Auto aftermarket remained soft on weak collision repair claims in both the U.S. and Europe.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Earnings per share | FY2025 | $7.75-$8.00 | $7.95-$8.05 | |
| Organic sales growth | FY2025 | Approximately 2% | Greater than 2% | |
| Adjusted operating margin expansion | FY2025 | 150-200 basis points | 180-200 basis points | |
| Free cash flow conversion | FY2025 | Greater than 100% | Greater than 100% (absolute dollars higher) | |
| New product launches | FY2025 | 215 target | Over 250 | |
| Transformation charges | Q4 2025 | $14 million in Q3 | About $15 million |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Q3 organic sales growth | 3.2% | Commercial excellence execution and NPI contribution; ~50 bps of the 70 bps beat versus the 2.5% plan was self-help, ~20 bps discrete timing from Q4 into Q3. |
| Q3 adjusted operating margin | Up 170 bps to 24.7% | ~$325 million benefit from volume, broad-based productivity and lower restructuring, partly offset by ~$50 million investments and ~$100 million tariff/stranded cost. |
| Q3 EPS | Up 10% to $2.19 | Strong operating performance ($0.25 contribution) partly offset by $0.04 from FX and non-operational items. |
| SIBG Q3 organic sales | Up 4.1% (highest since 2018 ex-COVID) | Electrical markets up low teens on data center construction, mid-single-digit IATD, and accelerating personal safety and abrasives. |
| TEBG Q3 organic sales | Up 3.6% (from 1% in H1) | Double-digit aerospace growth, electronics momentum (mainstream wins), auto flattish, plus a pavement-marking project timing shift. |
| China growth | Up high single digits (~8%) | Strength in industrial adhesives, films and electronics bonding solutions from strong local commercial execution; better than expected. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Portfolio shaping / divestitures | 2-3% of revenue under review for divestiture | Agreement to sell Precision Grinding & Finishing (less than 1% of sales, seven underutilized factories); not expected to be dilutive; process ongoing and disciplined. | |
| Restructuring / transformation | Enterprise program focused on short-term quick-payback actions | New longer-term redesign of manufacturing, distribution and business process services; $14 million Q3 charge, not a big bang; will be sized for 2026 in early next year. | |
| New product mix | Largely class three incremental line extensions (~80%) | Still ~80% class three but more class four/five adjacencies (e.g., electrical cable prep) entering the pipeline into 2026-2027. | |
| PFAS litigation | Public water supplier settled ($12.5 billion); AG cases progressing | Personal injury bellwether October trial date removed by judge to allow unfiled cases; just under 14,000 cases now being vetted. | |
| Tariffs | — | Net tariff impact ~$0.10 (gross ~$0.20), split 50/50 between price actions and cost; incremental 20 bps of price covering part of tariffs. |
Q&A summary
Why are new products delivering results without spending much more, and has the culture/compensation changed?
Greater pace, rigor and urgency over the last 18 months are tapping latent ideas; the funnel is healthy (130 products into the front end while launching 70, ~1,000 ideas). R&D spend is up only ~30 bps in the quarter, but more R&D dollars are shifting to new product development (from below 30% to ~35-36%); revenue impact will accelerate into 2026-2027.
Is this new restructuring the start of a multi-year project, and what should we expect in 2026?
It is a longer-term, more thoughtful redesign of manufacturing, distribution and business process services, structured over time rather than a big bang. The Q3 charge is $14 million, Q4 similar (~$15 million), with 2026 framing in early next year; the goal is accelerating margin expansion beyond 25% by 2027, and more opportunities are visible than at the February Investor Day.
Why the more-than-seasonal Q3-to-Q4 EPS drop despite good backlog coverage?
It is fairly typical: volume is usually ~$250 million lower in Q4 (consumer back-to-school, industrial seasonality) plus factory shutdowns affecting absorption. This year also has a step-up in investments (to $185 million for the year, mostly Q4) and tariffs in Q4. Year-over-year, 3M still expects to grow above macro in Q4.
Is essentially all growth coming from new products, and how is the margin contribution tracking?
The five-year new product sales metric (vitality) was up 3% in Q1, 15% in Q2, 30% in Q3 (16% YTD, high teens for the year), building toward 20% vitality by 2027. Most of the Q3 above-macro outperformance came from commercial effectiveness rather than NPI; NPI builds over time and is changing customer conversations and winning shelf space.
How repeatable is the SIBG commercial excellence playbook in other segments and on what timeline?
It started in SIBG (U.S. first, then Europe/Asia), with TBG drafting right behind and CBG building momentum. The three pillars are commercial management, channel effectiveness (driving the >$100 million cross-sell pipeline, ~$30 million closed), and loyalty/churn reduction. Still in early innings and will build over time.